Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Dopamine receptors - physiological understanding to therapeutic intervention potential
Autore:
Emilien, G; Maloteaux, JM; Geurts, M; Hoogenberg, K; Cragg, S;
Indirizzi:
Univ Catholique Louvain, Clin Univ St Luc, Pharmacol Lab, B-1200 Brussels,Belgium Univ Catholique Louvain Brussels Belgium B-1200 B-1200 Brussels,Belgium Univ Catholique Louvain, Clin Univ St Luc, Dept Neurol, B-1200 Brussels, Belgium Univ Catholique Louvain Brussels Belgium B-1200 B-1200 Brussels, Belgium Univ Groningen Hosp, Dept Internal Med, Div Endocrinol, NL-9700 RB Groningen, Netherlands Univ Groningen Hosp Groningen Netherlands NL-9700 RB ningen, Netherlands Univ Groningen Hosp, Div Diabet, NL-9700 RB Groningen, Netherlands Univ Groningen Hosp Groningen Netherlands NL-9700 RB ningen, Netherlands Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England Univ Oxford Oxford England OX1 3QT pt Pharmacol, Oxford OX1 3QT, England
Titolo Testata:
PHARMACOLOGY & THERAPEUTICS
fascicolo: 2, volume: 84, anno: 1999,
pagine: 133 - 156
SICI:
0163-7258(199911)84:2<133:DR-PUT>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
CONGESTIVE-HEART-FAILURE; LOW-DOSE DOPAMINE; PLACEBO-CONTROLLED EVALUATION; ACUTE MIGRAINE HEADACHE; PARKINSONS-DISEASE; DOUBLE-BLIND; D4 RECEPTOR; NOVELTY-SEEKING; RENAL-FUNCTION; MESSENGER-RNA;
Keywords:
dopamine receptors; neuroleptic; Parkinson's disease; migraine; schizophrenia; heart failure; renal failure;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
257
Recensione:
Indirizzi per estratti:
Indirizzo: Emilien, G 127 Rue Henri Prou, F-78340 Les Clayes Bois, France 127 Rue Henri Prou Les Clayes Bois France F-78340 ois, France
Citazione:
G. Emilien et al., "Dopamine receptors - physiological understanding to therapeutic intervention potential", PHARM THERA, 84(2), 1999, pp. 133-156

Abstract

There are two families of dopamine (DA) receptors, called D-1 and D-2, respectively. The D-1 family consists of D-1- and D-5-receptor subtypes and the D-2 family consists of D-2-, D-3-, and D-4-receptor subtypes. The amino acid sequences of these receptors show that they all belong to a large superfamily of receptors with seven transmembrane domains, which are coupled to their intracellular signal transduction systems by G-proteins. The implications of DA receptors in neuropsychiatry and cardiovascular and renal diseases are discussed. Neuropsychiatry indications include Parkinson's disease, schizophrenia, migraine, drug dependence, mania and depression, and Gilles de la Tourette syndrome. The underlying dysfunction of dopaminergic. systems and the potential benefits of dopaminergic therapy in these different indications are critically examined. With respect to the pharmacological treatment of Parkinson's disease, a range of DA agonists are in various stages of preclinical and clinical development. D-2-receptor agonist activity is predominant in most effective antiparkinsonian DA agonists. However, in practice, it is difficult to treat patients for several years with DA agonists alone; therapeutic benefit is not sustained. Rather, the use of a combination of DA agonists and levodopa is considered preferable. Reports of the efficacy of DA partial agonists await confirmation, and recent clinical investigations also suggest the potential of D-1 receptor agonists as antiparkinson drugs. Regarding migraine pathogenesis, clinical and pharmacological evidence suggests that DA is involved in this disorder. Most prodromal and accompanying symptoms may be related to dopaminergic activation. Several drugs acting on D-1 receptors are effective in migraine treatment. Furthermore, migraine patients show a higher incidence of dopaminergic symptoms followingacute DA agonist administration when compared with normal controls. In cardiology, the therapeutic benefits of DA agonists are noted in the treatmentof heart failure. Low doses of DA are widely used for its specific dopaminergic effects on renal function, which are suggested to be beneficial, and for its alpha- and beta-adrenergicmmedaate responses that occur with higherdoses. However, studies have been unable to demonstrate that DA can prevent acute renal failure or reduce mortality. It appears that the significant progress that is being made in the molecular understanding of DA receptors will continue to have a tremendous impact in the pharmacological treatment of neuropsychiatric, cardiovascular, and renal diseases. (C) 1999 Elsevier Science Inc. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/07/20 alle ore 03:04:26